Back to search results
NCT07618520

Expanding Genetic Access for Prostate Cancer Survivors

Not Yet Recruiting
NAAges 18–80InterventionalHealth services
Georgetown University
~500 participants
Updated 2026-06-01 on ClinicalTrials.gov
What's tested:Print Genetic Education GuideDigital Guide Genetic Education GuideEnhanced Usual Care

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Uptake of Germline Genetic Testing
Measured over 6-Months
+2 more outcomes measured

Conditions

Prostate Cancer Patients
Hereditary Cancer
Genetic Testing

Explore related trials

Prostate Carcinoma

Where it's being run

2 sites across 2 states
District of Columbia1
New Jersey1

Who to contact

Marc Schwartz
[email protected]
202-687-0185
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18-80 years of age
At least 6-months post diagnosis with prostate cancer
Have not had genetic testing for hereditary cancer
Have received care at one of the participating sites in the prior five years
Meet National Comprehensive Cancer Network criteria for germline GT
Able to read and speak in English
Capable of providing informed consent
Have internet access (via smartphone, tablet or computer)
Comfortable using a computer or mobile phone independently to access information

Exclusion

Do not speak English
Unable to access the Internet
Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)
Are unable to provide informed consent

What this trial measures

  • Uptake of Germline Genetic Testing6-Months

    As captured via internal RedCap form for the number or count of participants who opt for genetic testing during the six-month study period. The investigators will compare the three study arms to evaluate efficacy of the DG+ and Print+ interventions compared to EUC and to each other.

  • Survey Assessment of Impact of DG+ vs. Print+ vs. EUC1-Month and 6-Month surveys

    Evaluate the impact of the DG+ vs. Print+ vs. EUC on informed decision-making and psychosocial outcomes via survey measures of related constructs at 1-month and 6-month surveys. Multiple scales are used to measure this outcome and each scale has a unique scoring system.

  • Survey Assessment of Mediators and Moderators of EfficacyBaseline, 1-Month and 6-Month surveys

    Explore potential mechanisms by assessing mediators and moderators of efficacy via survey measures of related constructs at baseline, 1-month and 6-month surveys. Multiple scales are used to measure this outcome and each scale has a unique scoring system.